Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110α inhibitors

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 20, 2006, Pages 6847-6858

  Hayakawa, Masahiko ^a   Kaizawa, Hiroyuki ^a   Moritomo, Hiroyuki ^a   Koizumi, Tomonobu ^a   Ohishi, Takahide ^a   Okada, Minoru ^a   Ohta, Mitsuaki ^a   Tsukamoto, Shin ichi ^a   Parker, Peter ^b   Workman, Paul ^c   Waterfield, Mike ^d  

^a ASTELLAS PHARMA INC   (Japan)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

Cancer treatment; Inhibitor; p110 ; PI3 kinase

Indexed keywords

1 (6 HYDROXY 2 PHENYLQUINAZOLIN 4 YL)PIPERIDIN 4 ONE; 2 (2 AMINOPHENYL) 4 MORPHOLIN 4 YLQUINAZOLIN 6 OL; 2 (2 HYDROXYPHENYL) 4 MORPHOLIN 4 YLQUINAZOLIN 6 OL; 2 (3 AMINOPHENYL) 4 MORPHOLIN 4 YLQUINAZOLIN 6 OL; 2 (3 FLUOROPHENYL) 4 MORPHOLIN 4 YLQUINAZOLIN 6 OL; 2 (3 HYDROXYPHENYL) 4 MORPHOLIN 4 YLQUINAZOLIN 6 OL; 2 (3 METHOXYPHENYL) 4 MORPHOLIN 4 YLQUINAZOLIN 6 OL; 2 (4 AMINOPHENYL) 4 MORPHOLIN 4 YLQUINAZOLIN 6 OL; 2 (4 HYDROXYPHENYL) 4 MORPHOLIN 4 YLQUINAZOLIN 6 OL; 2 [(3 HYDROXYMETHYL)PHENYL] 4 MORPHOLIN 4 YLQUINAZOLIN 6 OL; 2 [(4 HYDROXYMETHYL)PHENYL] 4 MORPHOLIN 4 YLQUINAZOLIN 6 OL; 2 PHENYL 4 PIPERIDIN 1 YLQUINAZOLIN 6 OL; 3 (4 MORPHOLIN 4 YLQUINAZOLIN 2 YL)PHENOL; 3 (4 MORPHOLINOPYRIDO[3,2 D]PYRIMIDIN 2 YL)PHENOL; 3 (4 MORPHOLINOPYRIDO[3,4 D]PYRIMIDIN 2 YL)PHENOL; 3 (4 MORPHOLINOPYRIDO[4,3 D]PYRIMIDIN 2 YL)PHENOL; 3 (4 MORPHOLINOTHIENO[3,2 D]PYRIMIDIN 2 YL)PHENOL; 4 (4 HYDROXYPIPERIDIN 1 YL) 2 PHENYLQUINAZOLIN 6 OL; 4 [(2 METHOXYETHYL)AMINO] 2 PHENYLQUINAZOLIN 6 OL; 4 MORPHOLIN 4 YL 2 PHENYLQUINAZOLIN 5 OL; 4 MORPHOLIN 4 YL 2 PHENYLQUINAZOLIN 7 OL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN P110; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CATTLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; MOLECULAR STRUCTURE; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; QUINAZOLINES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33748096426     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.06.046     Document Type: Article

References (33)

1. Leevers S.J., Vanhaesebroeck B., and Waterfield M.D. Curr. Opin. Cell. Biol. 11 (1999) 219-225
2. Vanhaesebroeck B., Leevers S.J., Ahmadi K., Timms J., Katso R., Driscoll P.C., Woscholski R., Parker P.J., and Waterfield M.D. Annu. Rev. Biochem. 70 (2001) 535-602
3. Cantley L.C. Science 296 (2002) 1655-1657
4. Lawlor M.A., and Alessi D.R. J. Cell Sci. 114 (2001) 2903-2910
5. Hopkins K. Science 282 (1998) 1027-1030
6. Maehama T., and Dixon J.E. Trends Cell Biol. 9 (1999) 125
7. Simpson L., and Parsons R. Exp. Cell Res. 264 (2001) 29-41
8. Domin J., and Waterfield M.D. FEBS Lett. 410 (1997) 91-95
9. Vanhaesebroeck B., and Waterfield M.D. Exp. Cell Res. 253 (1999) 239-254
10. Vanhaesebroeck B., Leevers S.J., Panayatou G., and Waterfield M.D. Trends Biochem. Sci. 22 (1997) 267-272
11. Fruman D.A., Meyers R.E., and Cantley L.C. Annu. Rev. Biochem. 67 (1998) 481
12. Shayesteh L., Lu Y., Kuo W.-L., Baldocchi R., Godfrey T., Collins C., Pinkel D., Powell B., Mills G.B., and Gray J.W. Nat. Genet. 21 (1999) 99-102
13. Ma Y.-Y., Wei S.-J., Lin Y.-C., Lung J.-C., Chang T.-C., Whang-Peng J., Liu J.M., Yang D.-M., Yang W.K., and Schen C.-Y. Oncogene 19 (2000) 2739-2744
14. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., and Velculescu V.E. Science 304 (2004) 554
15. Campbell I.G., Russell S.E., Choong D.Y., Montgomery K.G., Ciavarella M.L., Hooi C.S., Cristiano B.E., Pearson R.B., and Phillips W.A. Cancer Res. 64 (2004) 7678-7681
16. Kang S., Bader A.G., and Vogt P.K. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 802-807
17. Parsons D.W., Wang T.-L., Samuels Y., Bardelli A., Cummins J.M., DeLong L., Silliman N., Ptak J., Szabo S., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., Lengauer C., and Velculescu V.E. Nature 436 (2005) 792
18. Schultz R.M., Merriman R.L., Andis S.L., Bonjouklian R., Grindey G.B., Rutherford P.G., Gallegos A., Massey L., and Powis G. Anticancer Res. 15 (1995) 1135-1139
19. Wymann M.P., Bulgarelli-Leva G., Zvelebil M.J., Pirola L., Vanhaesebroeck B., Waterfield M.D., and Panayotou G. Mol. Cell. Biol. 16 (1996) 1722-1733
20. Vlahos C.J., Matter W.F., Hui K.Y., and Brown R.F. J. Biol. Chem. 269 (1994) 5241-5248
21. Ward S., Sotsios Y., Dowden J., Bruce I., and Finan P. Chem. Biol. 10 (2003) 207-213
22. Ward S.G., and Finan P. Curr. Opin. Pharmacol. 3 (2003) 426-434
23. Tsizin Y.S., Karpova N.B., and Efimova O.V. Khim. Geterotsikl. Soedin. 7 (1971) 385-388
24. Hour M.-J., Huang L.-J., Kuo S.-C., Xia Y., Bastow K., Nakanishi Y., Hamel E., and Lee K.-H. J. Med. Chem. 43 (2000) 4479-4487
25. Tarzia G., Schiatti P., Selva D., Favara D., and Ceriani S. Eur. J. Med. Chem. 11 (1976) 263-270
26. Tanaka A., Terasawa T., Hagihara H., Sakuma Y., Ishibe N., Sawada M., Takasugi H., and Tanaka H. J. Med. Chem. 41 (1998) 2390-2410
27. Guither W.D., Coburn M.D., and Castle R.N. Heterocycles 12 (1979) 745-749
28. DeWolfe R.H., and Augustine F.B. J. Org. Chem. 30 (1965) 699-702
29. Sellstedt J.H., Guinosso C.J., Begany A.J., Bell S.C., and Rosenthale M. J. Med. Chem. 18 (1975) 926-933
30. Buscemi S., Pace A., and Vivona N. J. Org. Chem. 64 (1999) 7028-7033
31. Chapman N.B., Gibson G.M., and Mann F.G. J.Chem. Soc. (1947) 890-899
32. Zhou Z.-L., Navratil J.M., Cai S.X., Whittemore E.R., Espitia S.A., Hawkinson J.E., Tran M., Woodward R.M., Weber E., and Keana J.F.W. Bioorg. Med. Chem. 9 (2001) 2061-2071
33. Leroy F., Despres P., Bigan M., and Blondeau D. Synth. Commun. 26 (1996) 2257-2272